爆炸性的行情之下,创新药行业又进入了狂欢阶段,动辄几倍涨幅的Biotech比比皆是。在这样的氛围下,再鼎医药似乎显得过于低调,300多亿港元的市值与上一轮狂欢超千亿市值也无法相比,这或许与本轮医药牛市以License-out为驱动有关。在这份低调背后,却是再鼎医药蜕变的关键期,上半年成绩单即将出炉,或许离正式盈利还差点火候。但在业绩高增长趋势下,模式之争的答案就要揭晓。精进与超越2014年,...
Source Link爆炸性的行情之下,创新药行业又进入了狂欢阶段,动辄几倍涨幅的Biotech比比皆是。在这样的氛围下,再鼎医药似乎显得过于低调,300多亿港元的市值与上一轮狂欢超千亿市值也无法相比,这或许与本轮医药牛市以License-out为驱动有关。在这份低调背后,却是再鼎医药蜕变的关键期,上半年成绩单即将出炉,或许离正式盈利还差点火候。但在业绩高增长趋势下,模式之争的答案就要揭晓。精进与超越2014年,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.